CASI Pharma (CASI) Misses Q3 EPS by 2c

CASI Pharma (NASDAQ: CASI) reported Q3 EPS of ($0.07), $0.02 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $8.1 million versus the consensus estimate of $7.54 million.

For earnings history and earnings-related data on CASI Pharma (CASI) click here.

You May Also Be Interested In

• NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
• Nike (NKE) Tops Q4 EPS by 8c
• Goldman Sachs on Titan Company (TTAN:IN): 'Lower gold prices could also create earnings tailwinds'